{
    "nct_id": "NCT03847311",
    "official_title": "Double Blind Trial Investigating the Role of Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients",
    "inclusion_criteria": "* Adult patient age 18 - <95 years old capable of understanding and providing consent in English and capable of complying with the outcome used.\n* Diagnosis of cancer with pain moderate to severe pain on stable doses of opioids\n* 3-day average numeric pain rating score (NPRS) for pain of at least 5/10 at baseline evaluation.\n* Patient consents to double blind design of the experiment in a shared decision- making process with the treating physician.\n* Pain duration of at least 6 weeks or more.\n* Prognosis greater than 6 months.\n* Able to take oral medication\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 94 Years",
    "exclusion_criteria": "* Those receiving remuneration for their pain treatment (e.g., disability, worker's compensation).\n* Those involved in active litigation relevant to their pain.\n* Subjects with intestinal or urinary obstruction or at risk of such disorders.\n* Porphyria\n* Blood dyscrasias, hepatic or renal disease.\n* Taking medications that may interact with sulfasalazine.\n* Taking Lapatinib or Digoxin.\n* No sustained hypercalcemia.\n* Hypersensitivity to sulfasalazine, its metabolites, sulfonamides, or salicylates.\n* The Subject is incarcerated.\n* Those unable to read English and complete the assignment in English.\n* Addictive behavior, severe clinical depression, or psychotic features.\n* Possible pregnancy or lactation.",
    "miscellaneous_criteria": ""
}